Delhi HC: Hymen Rupture is Not Required to Prove Penetrative Sexual Assault under the POCSO Act  ||  Delhi HC: Organised Crime Groups Exploit Juveniles, Misuse Juvenile Justice Laws for Serious Crimes  ||  Patna HC Directs Smooth Lok Adalat For Traffic Challan Settlement, Ensuring Access to Justice  ||  Supreme Court Holds Revenue Records Alone Do Not Confer Title Over Land Ownership  ||  SC: Disciplinary Authority Cannot Punish Employee Without Fresh Show-Cause Notice on New Charges  ||  Supreme Court: No Separate Plea is Needed to Cancel Agreement to Sell For Buyer’s Default  ||  Supreme Court Directs District Collectors to Strictly Implement Solid Waste Management Rules 2026  ||  Bombay HC: Courts Cannot Mandate Mediation under Mediation Act 2023 Without Mutual Consent  ||  Kerala HC: Embassy NOC Not Required For Indian-Foreigner Marriage under Special Marriage Act  ||  MP High Court: Penalty May Stand if Misconduct is Proven, Even if Inquiry is Vitiated    

Glenmark Settles Patent Litigation over Milnacipran Hydrochloride Tablets - (22 Dec 2015)

Glenmark Pharmaceuticals Inc., USA have entered into a settlement agreement with Forest Laboratories, LLC, Forest Laboratories Holdings, and Royalty Pharma Collection Trust to settle and dismissed outstanding patent litigation related to Glenmark's Abbreviated New Drug Application.

Tags : GLENMARK PHARMACEUTICALS INC   FOREST LABORATORIES   LLC   FOREST LABORATORIES HOLDINGS     ROYALTY PHARMA COLLECTION TRUST  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved